Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)

Roth, Arnaud; Maibach, R; Martinelli, G; Fazio, N; Aapro, M S; Pagani, O; Morant, R; Borner, M M; Herrmann, R; Honegger, H; Cavalli, F; Alberto, Pierre; Castiglione, M; Goldhirsch, A

doi:10.1023/A:1008342013224

Scientific article

English

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)

ContributorsRoth, Arnaud; Maibach, R; Martinelli, G; Fazio, N; Aapro, M S; Pagani, O; Morant, R; Borner, M M; Herrmann, R; Honegger, H; Cavalli, F; Alberto, Pierre; Castiglione, M; Goldhirsch, A

Published inAnnals of oncology, vol. 11, no. 3, p. 301-306

Publication date2000

Abstract

A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC).

Keywords

Adenocarcinoma/drug therapy/mortality/secondary
Antineoplastic Combined Chemotherapy Protocols/adverse effects/therapeutic use
Cisplatin/administration & dosage/adverse effects
Humans
Paclitaxel/administration & dosage/adverse effects/analogs & derivatives
Stomach Neoplasms/drug therapy/mortality/pathology
Survival Analysis
Taxoids

NoteOpen Access - Licence nationale Oxford University Press

Affiliation entities

Research groups

Groupe Roth Arnaud (oncologie) (285)

Citation (ISO format)

ROTH, Arnaud et al. Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO). In: Annals of oncology, 2000, vol. 11, n° 3, p. 301–306. doi: 10.1023/A:1008342013224

Article (Published version)

OA NATIONAL

Identifiers

PID : unige:55288
DOI : 10.1023/A:1008342013224
PMID : 10811496

Additional URL for this publicationhttp://annonc.oxfordjournals.org/content/11/3/301.long

Journal ISSN0923-7534

427views

191downloads

Creation08/04/2015 16:43:00

First validation08/04/2015 16:43:00

Update time23/11/2023 08:58:04

Status update23/11/2023 08:58:04

Last indexation30/10/2024 23:50:18

Archive ouverte UNIGE

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)

A multi-centric trial was performed to explore the clinical activity, in terms of response and toxicity (primary objectives), duration of response and survival (secondary objectives), of docetaxel with cisplatin in advanced gastric cancer (AGC).

Technical informations